Mouse antithrombotic assay. Inhibition of platelet thromboembolism by disintegrins.
The mouse antithrombotic assay represents a model of fatal pulmonary thromboembolism induced by intravenous injection of collagen and epinephrine. Mice were protected by low doses of two disintegrins, albolabrin (10 micrograms/mouse) and eristostatin (0.6 micrograms/mouse), whereas high doses of a thrombin inhibitor and an inhibitor of von Willebrand Factor binding to glycoprotein Ib were not effective. Injection of collagen and epinephrine resulted in the drop of platelet count and accumulation of platelet aggregates in the lung that appears to be the immediate cause of death. Albolabrin or eristostatin administration did not prevent the decrease of platelet count. Injection of albolabrin resulted in the formation of smaller and reversible platelet aggregates in the lungs and decreased accumulation of 51Cr-labeled platelets in the lung suggesting that this disintegrin decreases formation of platelet aggregates in vivo. We compared the effects of albolabrin and erisostatin on platelet aggregation, tail bleeding time, and survival of challenged animals. Eristostatin was about 5 times more potent in inhibiting platelet aggregation in vitro than albolabrin and 38 times more potent than albolabrin in protecting animals from sudden death. Both disintegrins, at the same doses (0.6-5 micrograms/mouse), caused similar dose-dependent prolongation of the bleeding time; however, only eristostatin exerted a protective effect. In conclusion, a) the mouse antithrombotic assay is a suitable model to screen and to evaluate the potency of platelet fibrinogen receptor antagonists in vivo; b) the results of the antithrombotic assay correlate better with the inhibition of platelet aggregation in vitro than with the prolongation of bleeding time.
Beviglia
L
L
Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro (Chieti), Italy.
Poggi
A
A
Rossi
C
C
McLane
M A
MA
Calabrese
R
R
Scanziani
E
E
Cook
J J
JJ
Niewiarowski
S
S
D000590:Amino Acid Chloromethyl Ketones / Q000494:pharmacology; D000818:Animals; D001760:Bleeding Time; D003094:Collagen / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004837:Epinephrine / Q000633:toxicity; D008297:Male; D051379:Mice; D009842:Oligopeptides / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors*; D011655:Pulmonary Embolism / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D012910:Snake Venoms; D014757:Viper Venoms / Q000494:pharmacology / Q000627:therapeutic use*; D014841:von Willebrand Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology
D000590:Amino Acid Chloromethyl Ketones; D009842:Oligopeptides; D010446:Peptide Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D012910:Snake Venoms; D014757:Viper Venoms; D014841:von Willebrand Factor; C081839:von Willebrand factor (445-733); C064595:albolabrin; C084060:eristostatin; D003094:Collagen; C046617:arginyl-glycyl-aspartyl-serine; C040308:phenylalanyl-prolyl-arginine-chloromethyl ketone; D004837:Epinephrine